{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:22:26Z","timestamp":1783167746131,"version":"3.54.6"},"publisher-location":"New York, NY","reference-count":35,"publisher":"Springer US","isbn-type":[{"value":"9781071631744","type":"print"},{"value":"9781071631751","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3175-1_37","type":"book-chapter","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:13Z","timestamp":1684479733000},"page":"569-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B"],"prefix":"10.1007","author":[{"given":"Sunil","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"37_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.1333","volume":"104","author":"RA Marlar","year":"2020","unstructured":"Marlar RA, Strandberg K, Shima M et al (2020) Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B. Eur J Haematol 104:3\u201314. https:\/\/doi.org\/10.1111\/ejh.1333","journal-title":"Eur J Haematol"},{"issue":"3","key":"37_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MBC.0000000000000885","volume":"31","author":"A Chhabra","year":"2020","unstructured":"Chhabra A, Spurden D, Fogarty PF et al (2020) Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis 31(3):186\u2013192. https:\/\/doi.org\/10.1097\/MBC.0000000000000885","journal-title":"Blood Coagul Fibrinolysis"},{"key":"37_CR3","first-page":"141","volume":"36","author":"MC Ar","year":"2019","unstructured":"Ar MC, Balkan C, KavaklI K (2019) Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Hematol 36:141\u2013154","journal-title":"Turk J Hematol"},{"key":"37_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jth.12506","volume":"12","author":"TE Coyle","year":"2014","unstructured":"Coyle TE, Reding MT, Lin JC et al (2014) Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 12:488\u2013496. https:\/\/doi.org\/10.1111\/jth.12506","journal-title":"J Thromb Haemost"},{"key":"37_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/hae.13970","volume":"26","author":"Y Brennan","year":"2020","unstructured":"Brennan Y, Parikh S, McRae S et al (2020) The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors\u2019 Organisation. Haemophilia 26:529\u2013535. https:\/\/doi.org\/10.1111\/hae.13970","journal-title":"Haemophilia"},{"key":"37_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/hae.13438","volume":"24","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Young G, Hermans C et al (2018) Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia 24:348\u2013358","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"37_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A et al (2020) WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 26(Suppl 6):1\u2013158","journal-title":"Haemophilia"},{"key":"37_CR8","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/ijlh.12953","volume":"41","author":"AE Bowyer","year":"2018","unstructured":"Bowyer AE, Shepherd MF, Kitchen S et al (2018) Measurement of extended half-life recombinant factor IX products in clinical practice. Int J Lab Hem 41:e46\u2013e49. https:\/\/doi.org\/10.1111\/ijlh.12953","journal-title":"Int J Lab Hem"},{"key":"37_CR9","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/jth.15425","volume":"19","author":"MV Ovanesov","year":"2021","unstructured":"Ovanesov MV, Jackson JW, Golding B et al (2021) Considerations on activity assay discrepancies in factor VIII and factor IX products. J Thromb Haemost 19:2102\u20132111. https:\/\/doi.org\/10.1111\/jth.15425","journal-title":"J Thromb Haemost"},{"key":"37_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/hae.12634","volume":"21","author":"J Dodt","year":"2015","unstructured":"Dodt J, Hubbard AR, Wicks SJ et al (2015) Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 21:543\u2013549. https:\/\/doi.org\/10.1111\/hae.12634","journal-title":"Haemophilia"},{"key":"37_CR11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/jth.12167","volume":"11","author":"AR Hubbard","year":"2013","unstructured":"Hubbard AR, Dodt J, Lee T et al (2013) On behalf of the factor VIII and factor IX Subcommittee of the Scientific and Standardisation committee of the international society on thrombosis and haemostasis. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 11:988\u2013989","journal-title":"J Thromb Haemost"},{"key":"37_CR12","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1111\/hae.13556","volume":"24","author":"HV Wilmot","year":"2018","unstructured":"Wilmot HV, Gray E (2018) Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent. Haemophilia 24:e363\u2013e368. https:\/\/doi.org\/10.1111\/hae.13556","journal-title":"Haemophilia"},{"key":"37_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/hae.13813","volume":"25","author":"S Tiefenbacher","year":"2019","unstructured":"Tiefenbacher S, Clausen WHO, Hansen M et al (2019) A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories. Haemophilia 25:893\u2013901. https:\/\/doi.org\/10.1111\/hae.13813","journal-title":"Haemophilia"},{"key":"37_CR14","unstructured":"Raut S, Daniels S, Heath A (2009) An international collaborative study to assign value to the 8th WHO international standard for blood coagulation factor VIII concentrate (07\/350). World Health Organisation and WHO expert committee on biological standardisation. WHO\/BS\/09.2117. https:\/\/apps.who.int\/iris\/handle\/10665\/70137. Accessed 03 Nov 2022"},{"issue":"Suppl. 1","key":"37_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ijlh.12813","volume":"40","author":"D Van den Bossche","year":"2018","unstructured":"Van den Bossche D, Peerlinck K, Jacquemin M (2018) New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hem 40(Suppl. 1):21\u201329","journal-title":"Int J Lab Hem"},{"key":"37_CR16","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1111\/hae.14038","volume":"26","author":"G Kershaw","year":"2020","unstructured":"Kershaw G, Chen VM, Khoo T-L (2020) Australian comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein (Eloctate\u00ae). Haemophilia 26:e226\u2013e229","journal-title":"Haemophilia"},{"issue":"2","key":"37_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/rth2.12046","volume":"1","author":"E Persson","year":"2017","unstructured":"Persson E, La Cour CC (2017) Underestimation of N-glycoPEGylated factor IX one-stage clotting activity owing to contact activator-impaired activation. Res Pract Thromb Haemost 1(2):259\u2013263. https:\/\/doi.org\/10.1002\/rth2.12046","journal-title":"Res Pract Thromb Haemost"},{"key":"37_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/hae.12374","volume":"20","author":"J-M Gu","year":"2014","unstructured":"Gu J-M, Ramsey P, Evans V et al (2014) Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 20:593\u2013600. https:\/\/doi.org\/10.1111\/hae.12374","journal-title":"Haemophilia"},{"key":"37_CR19","unstructured":"Attachment 1: TGA Product AusPAR (2018) Afstyla Lonoctocog alfa CSR Behring Australia Pty Ltd PM- 2015-04357-1-4 Final. https:\/\/www.tga.gov.au\/product-information-pi. Accessed 07 July 2022"},{"key":"37_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13013","volume":"22","author":"P Collins","year":"2016","unstructured":"Collins P, Chalmers E, Chowdary P et al (2016) The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia 22:487\u2013498","journal-title":"Haemophilia"},{"key":"37_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/jth.15705","volume":"20","author":"J Voorberg","year":"2022","unstructured":"Voorberg J, Postmus T, Schols S (2022) Next generation FVIII mimetic bispecific antibody for Hemophilia A. J Thromb Haemost 20:1301\u20131305. https:\/\/doi.org\/10.1111\/jth.15705","journal-title":"J Thromb Haemost"},{"key":"37_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1055\/a-1665-6232","volume":"42","author":"J M\u00fcller","year":"2022","unstructured":"M\u00fcller J, Miesbach W, Pr\u00fcller F et al (2022) An update on laboratory diagnostics in haemophilia A and B. Hamostaseologie (OA) 42:248\u2013260. https:\/\/doi.org\/10.1055\/a-1665-6232","journal-title":"Hamostaseologie (OA)"},{"key":"37_CR23","unstructured":"Medical Literature \u2013 Roche Products Pty Ltd Australia (2022) Hemlibra \u00ae (emicizumab) use with bovine chromogenic assays, Ref. 01999588. Accessed 12 Sep 2022"},{"key":"37_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jth.13215","volume":"4","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Oldenburg J, Friedman KD (2016) A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 4:248\u2013261","journal-title":"J Thromb Haemost"},{"key":"37_CR25","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1111\/jth.14315","volume":"16","author":"M Makris","year":"2018","unstructured":"Makris M, Oldenburg J, Mauser-Bunschoten EP et al (2018) For the subcommittee on factor VIII, factor IX and rare bleeding disorders. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J Thromb Haemost 16:2530\u20132533","journal-title":"J Thromb Haemost"},{"key":"37_CR26","unstructured":"TGA Australian product information (2022) Adynovate\u00ae (Rurioctocog alfa pegol) Takeda Pharmaceuticals Australia Pty Ltd. Adynovate PI V2.0 CCDS 6.0. https:\/\/www.tga.gov.au\/resources\/artg\/300850. Accessed 13 April 2022"},{"key":"37_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/hae.13897","volume":"26","author":"M Ezban","year":"2020","unstructured":"Ezban M, Hansen M, Kjalke M (2020) An overview of turoctocog alfa pegol (N8-GP; ESPEROCT\u00ae) assay performance: implications for postadministration monitoring. Haemophilia 26:156\u2013163. https:\/\/doi.org\/10.1111\/hae.13897","journal-title":"Haemophilia"},{"key":"37_CR28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/hae.13834","volume":"25","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, Garagiola I, Boscarino M et al (2019) Real-life experience in switching to new extended half-life products at European haemophilia centres. Haemophilia 25:946\u2013952. https:\/\/doi.org\/10.1111\/hae.13834","journal-title":"Haemophilia"},{"key":"37_CR29","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1111\/jth.13787","volume":"15","author":"S Tiefenbacher","year":"2017","unstructured":"Tiefenbacher S, Bohra R, Amiral J et al (2017) Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog betapegol. J Thromb Haemost 15:1901\u20131912","journal-title":"J Thromb Haemost"},{"issue":"03","key":"37_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-0037-1598058","volume":"43","author":"S Kitchen","year":"2017","unstructured":"Kitchen S, Tiefenbacher S, Gosselin R (2017) Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 43(03):331\u2013337","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"37_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1365-2516.2010.02481.x","volume":"17","author":"D Viuff","year":"2011","unstructured":"Viuff D, Barrowcliffe T, Saugstrup T et al (2011) International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 17(4):695\u2013702","journal-title":"Haemophilia"},{"key":"37_CR32","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/jth.13375","volume":"14","author":"W Pickering","year":"2016","unstructured":"Pickering W, Hansen M, Kjalke M et al (2016) Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP. J Thromb Haemost 14:1579\u20131587","journal-title":"J Thromb Haemost"},{"key":"37_CR33","unstructured":"Attachment 1: TGA Product AusPAR (2019) REFIXIA \u2013 nonacog beta pegol \u2013 Novo Nordisk Pharmaceuticals Pty Ltd \u2013 PM-2018-02720-1-6 FINAL. https:\/\/www.tga.gov.au\/product-information-pi. Accessed 14 Oct 2022"},{"key":"37_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/jth.14332","volume":"17","author":"C Horn","year":"2019","unstructured":"Horn C, Negrier C, Kalina U et al (2019) Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost 17:138\u2013148","journal-title":"J Thromb Haemost"},{"key":"37_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8768074","volume":"2020","author":"TM Owaidah","year":"2020","unstructured":"Owaidah TM, Alzahrani HA, Al-Numair NS (2020) Assessing the performance of extended half-life coagulation factor VIII, FC fusion protein by using chromogenic and one-stage assays in Saudi Hemophilia A Patients. Advances in Haematology (OA) 2020:1\u20137. https:\/\/doi.org\/10.1155\/2020\/8768074","journal-title":"Advances in Haematology (OA)"}],"container-title":["Methods in Molecular Biology","Hemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3175-1_37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:06:58Z","timestamp":1684480018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3175-1_37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631744","9781071631751"],"references-count":35,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_37","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"20 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}